0 items

in your cart
$0.00

  • Search for Medications
  • Viewcart | Checkout
  • Manage Account
  •  
  • Click-to-Call  

Prescription Drug Search

Strengths available for Rimonabant :

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about SaveRxCanada.to

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Rimonabant:

  • Armenia
  • Australia
  • Azerbaijan
  • Bahrain
  • Belarus
  • Brazil
  • Chile
  • China
  • Costa Rica
  • Ecuador
  • Estonia
  • European Union
  • Fiji
  • Germany
  • Greece
  • Greenland
  • Grenada
  • Guatemala
  • Hungary
  • India
  • Indonesia
  • Iran
  • Latvia
  • Lebanon
  • Liechtenstein
  • Lithuania
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Portugal
  • Romania
  • Saint Lucia
  • Thailand
  • Trinidad and Tobago
  • United Arab Emirates
  • United Kingdom, UK
  • United States, US
  • Uzbekistan
  • Venezuela
View All Countries

Latest news releases on Rimonabant:

Rimonabant - Wikipedia

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.

Rimonabant | C22H21Cl3N4O - PubChem

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world.

Rimonabant - an overview | ScienceDirect Topics

Rimonabant has been reported to cause partial seizures in a patient with a history of generalized epilepsy [115 A]. A 52-year-old obese man with hypertension, diabetes mellitus, and a history of absences and two generalized tonic–clonic seizures at ages 4–15 years, but who had been seizure free for over 20 years took rimonabant 20 mg/day and 2 months later started to have nocturnal partial ...

Acomplia: Uses, Dosage, Side Effects & Warnings - Drugs.com

Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines Agency (EMEA) in January 2009 due to the risks of dangerous psychological side effects, including suicidality. Previously, the EMEA had suspended Acomplia from the UK market in 2008 because the agency felt the benefits did not ...

Rimonabant - DrugBank

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.

The psychiatric side-effects of rimonabant.

1. Braz J Psychiatry. 2009 Jun;31(2):145-53. The psychiatric side-effects of rimonabant. Moreira FA(1), Crippa JA. Author information: (1)Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. OBJECTIVE: Experimental evidence has suggested that drugs that enhance cannabinoid type-1 (CB1) receptor activity may induce ...

Rimonabant | SpringerLink

Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or dyslipidaemia, oral rimonabant 20mg once daily ...

Rimonabant | ≥99%(HPLC) | Selleck | Cannabinoid Receptor ...

Rimonabant (SR141716) is the first selective and orally active antagonist of the central brain cannabinoid receptor (CB1) with IC50 with 13.6 nM and EC50 with 17.3 nM in hCB1 transfected HEK 293 membrane.Find all the information about Rimonabant (SR141716) for cell signaling research.

Rimonabant - Wikipedia, la enciclopedia libre

Rimonabant (conocido también como SR141716), [n 1] es un inhibidor del apetito que actualmente se encuentra fuera del mercado en gran parte del mundo. Este es un antagonista selectivo del receptor cannabinoide CB1. [1] Su principal efecto es la reducción del apetito.. Rimonabant fue el primer bloqueador del receptor selectivo CB1 en ser aprobado en el mundo.

リモナバン - Wikipedia

リモナバン(リモナバント, 英語: Rimonabant, SR141716)は、選択的な カンナビノイド受容体タイプ1 (英語版) の拮抗薬で、食欲 抑制剤または抗肥満薬 である。 かつての製品名はアコンプリア(Acomplia)やスリモナ(Slimona)。

Customer Service
1-866-799-3435 | Contact Form
Copyright © 2020 SaveRxCanada.to All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK